FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
30.0 ptn (24u)Health & MedicineOne-Off3mnd
KalshiBeschikbaarheid controlerenKYC vereist2% kostenGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdHuidige impliciete kans
Ja 97%+30.0pt
Marktkwaliteit
45 / 100
Lage kwaliteit24u volume
€ 539,3
Liquiditeit
€ 594,2
Lage liquiditeitBied / Laat
72.0% / 80.0%
Spread
8.0 pt
Brede spreadMarktdata
Bijgewerkt 7 minuten geleden
17 jun 26, 21:30 UTC1 jan 27, 04:59 UTC
Trends
Gerelateerde Markten
Gerelateerde vragen voor context, geen vergelijking van gelijkwaardige contracten.
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiFDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketRegels
If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Afwikkeling via:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars.
- Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial.
- In the EPICS-III trial , it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.
Open markten
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Totaal volume
- € 15,6 mln.
- 24u volume
- € 18,3K
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Totaal volume
- € 1,6 mln.
- 24u volume
- € 5,2K
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 extra uitkomsten
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Totaal volume
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Totaal volume
- € 916K
- 24u volume
- € 1,5K
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 extra uitkomsten
- Totaal volume
- € 863,6K
- 24u volume
- € 1K
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
Veelgestelde vragen
- Wat zijn de huidige kansen voor FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)?
- Kalshi prijst Yes op 97% per 8 september 2026.
- Wanneer wordt FDA decision: Saroglitazar by Zydus Therapeutics (in 2026) afgewikkeld?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026) wordt naar verwachting op 1 januari 2027 afgewikkeld.
- Hoe wordt FDA decision: Saroglitazar by Zydus Therapeutics (in 2026) afgewikkeld?
- Kalshi wikkelt deze markt als volgt af: If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.